Publication | Closed Access
P109 Efficacy and safety of a 3-monthly depot formulation of degarelix compared with goserelin in prostate cancer
11
Citations
0
References
2012
Year
UrologyMedicinePharmacology3-Monthly Depot FormulationPharmacotherapyP109 EfficacyAnti-cancer AgentProstatic DiseaseOncologyCancer Research
No additional data available for this publication yet. Check back later!